Morgan Stanley
UBX

Morgan Stanley’s Unity Biotechnology UBX Stock Holding History

Morgan Stanley’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,556
Closed -$23.3K – 8379
2025
Q2 		$23.3K Buy
60,556
+17,200
+40% +$14.7K ﹤0.01% 6607
2025
Q1 		$45.1K Sell
43,356
-36,685
-46% -$66.3K ﹤0.01% 6304
2024
Q4 		$78.2K Buy
80,041
+35,350
+79% +$43.9K ﹤0.01% 6148
2024
Q3 		$65.7K Sell
44,691
-8,517
-16% -$12.5K ﹤0.01% 6137
2024
Q2 		$71.8K Buy
53,208
+15,798
+42% +$24K ﹤0.01% 6069
2024
Q1 		$61.4K Sell
37,410
-36,110
-49% -$62.7K ﹤0.01% 6139
2023
Q4 		$142K Buy
73,520
+42,874
+140% +$79.7K ﹤0.01% 6056
2023
Q3 		$73.6K Sell
30,646
-15,768
-34% -$41.8K ﹤0.01% 6011
2023
Q2 		$118K Sell
46,414
-1,037
-2% -$2.74K ﹤0.01% 5873
2023
Q1 		$77.3K Buy
47,451
+2,397
+5% +$9.61K ﹤0.01% 6108
2022
Q4 		$123K Buy
45,054
+26,846
+147% +$78K ﹤0.01% 5888
2022
Q3 		$72K Buy
18,208
+3,469
+24% +$21.9K ﹤0.01% 6238
2022
Q2 		$82K Buy
14,739
+325
+2% +$2.71K ﹤0.01% 6380
2022
Q1 		$161K Sell
14,414
-2,917
-17% -$32.7K ﹤0.01% 6039
2021
Q4 		$253K Sell
17,331
-32,619
-65% -$713K ﹤0.01% 5938
2021
Q3 		$1.5M Sell
49,950
-41,507
-45% -$1.46M ﹤0.01% 4788
2021
Q2 		$4.24M Buy
91,457
+74,683
+445% +$3.6M ﹤0.01% 3953
2021
Q1 		$1.01M Sell
16,774
-22,891
-58% -$1.56M ﹤0.01% 4728
2020
Q4 		$2.08M Buy
39,665
+28,491
+255% +$1.37M ﹤0.01% 4122
2020
Q3 		$387K Sell
11,174
-6,486
-37% -$411K ﹤0.01% 4766
2020
Q2 		$1.53M Buy
17,660
+11,616
+192% +$861K ﹤0.01% 3833
2020
Q1 		$351K Sell
6,044
-15,993
-73% -$1.01M ﹤0.01% 4579
2019
Q4 		$1.59M Buy
22,037
+14,566
+195% +$1.03M ﹤0.01% 4213
2019
Q3 		$455K Sell
7,471
-3,791
-34% -$268K ﹤0.01% 4726
2019
Q2 		$1.07M Sell
11,262
-33,666
-75% -$2.86M ﹤0.01% 4178
2019
Q1 		$3.64M Buy
44,928
+37,255
+486% +$4.23M ﹤0.01% 3015
2018
Q4 		$1.25M Sell
7,673
-4,775
-38% -$634K ﹤0.01% 4119
2018
Q3 		$2.03M Buy
12,448
+7,984
+179% +$1.31M ﹤0.01% 3988
2018
Q2 		$672K Buy
+4,464
New +$653K ﹤0.01% 4895

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Morgan Stanley's UBX Position: Q3 2025 in Review

Morgan Stanley sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 60,556 shares — an estimated $23.3K sold.

Morgan Stanley first reported a position in UBX in Q2 2018 and held it in 29 quarters. The position peaked at $4.24M in Q2 2021. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Morgan Stanley reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 60,556 Unity Biotechnology shares in Q3 2025, an estimated $23.3K.
  • Morgan Stanley first reported a position in Unity Biotechnology in Q2 2018 and held it in 29 quarters.
  • Morgan Stanley's Unity Biotechnology position peaked at $4.24M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.